PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Keppler-Hafkemeyer, A.* ; Greil, C.* ; Wratil, P.R.* ; Shoumariyeh, K.* ; Stern, M.* ; Hafkemeyer, A.* ; Ashok, D.* ; Hollaus, A.* ; Lupoli, G.* ; Priller, A.* ; Bischof, M.L.* ; Ihorst, G.* ; Engelhardt, M.* ; Marks, R.* ; Finke, J.* ; Bertrand, H.* ; Dächert, C.* ; Muenchhoff, M.* ; Badell, I.* ; Emmerich, F.* ; Halder, H.* ; Spaeth, P.M.* ; Knolle, P.A.* ; Protzer, U. ; von Bergwelt-Baildon, M.* ; Duyster, J.* ; Hartmann, T.N.* ; Moosmann, A. ; Keppler, O.T.*

Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma.

Nat. Cancer 4, 81–95 (2023)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Individuals with hematologic malignancies are at increased risk for severe coronavirus disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity are scarce. Here we present an observational study with expanded methodological analysis of a longitudinal, primarily BNT162b2 mRNA-vaccinated cohort of 60 infection-naive individuals with B cell lymphomas and multiple myeloma. We show that many of these individuals, despite markedly lower anti-spike IgG titers, rapidly develop potent infection neutralization capacities against several severe acute respiratory syndrome coronavirus 2 variants of concern (VoCs). The observed increased neutralization capacity per anti-spike antibody unit was paralleled by an early step increase in antibody avidity between the second and third vaccination. All individuals with hematologic malignancies, including those depleted of B cells and individuals with multiple myeloma, exhibited a robust T cell response to peptides derived from the spike protein of VoCs Delta and Omicron (BA.1). Consistently, breakthrough infections were mainly of mild to moderate severity. We conclude that COVID-19 vaccination can induce broad antiviral immunity including ultrapotent neutralizing antibodies with high avidity in different hematologic malignancies.
Impact Factor
Scopus SNIP
Altmetric
22.700
2.840
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Sprache englisch
Veröffentlichungsjahr 2023
Prepublished im Jahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 2662-1347
e-ISSN 2662-1347
Zeitschrift Nature Cancer
Quellenangaben Band: 4, Heft: , Seiten: 81–95 Artikelnummer: , Supplement: ,
Verlag Springer
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Gene Vector (AGV)
Institute of Virology (VIRO)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-501500-001
G-502700-003
DOI 10.1038/s43018-022-00502-x
Scopus ID 85144425353
PubMed ID 36543907
Erfassungsdatum 2023-01-10
[➜Korrektur melden]